Zhang XG 2011.

Methods	Country: China Setting: outpatients Aim: to observe the effects of Bushenjianpi Zhuangguyin in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T‐test Loss to follow‐up: not reported
Participants	Ethnicity: Chinese 100 primary osteoporosis patients enrolled: 50 in trial group, 50 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: secondary osteoporosis, disease‐affected bone metabolism, etc.
Interventions	Experimental: Bushenjianpi Zhuangguyin, 1 dose per day, water fried, twice a day, for 12 weeks Control: Caltrate, 600 mg, twice a day, and Miacalcin ampoule 50 IU, once a day, for 12 weeks
Outcomes	BMD, Ca, P, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated